RxDoctor Payments Data

Vijayalaksami Reddy, MD

Internal Medicine · Baltimore, MDNPI 1992869572

Payments from drug & device makers

$14,889in general payments, 2019–2025

Across 608 payments — averaging $24.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$2K
  • AstraZeneca$1K
  • AbbVie$1K
  • Johnson & Johnson$1K
  • Kowa Pharmaceuticals America, Inc.$860
  • Amgen$829
  • plus $7K from 34 others

What the payments were for

  • Food & beverage$14,75599%
  • Education$1341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,889 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$93,294
Medicare patients
68
Services billed
919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala35$143,287
GlatopaGlatiramer Acetate12$58,429
TriumeqAbacavir/Dolutegravir/Lamivudi12$45,204
JanuviaSitagliptin Phosphate56$32,514
EliquisApixaban39$23,009
FarxigaDapagliflozin Propanediol73$21,188
EntrestoSacubitril/Valsartan63$18,448
OzempicSemaglutide19$16,216
TrulicityDulaglutide14$14,007
LinzessLinaclotide23$11,777
Soliqua 100-33Insulin Glargine/Lixisenatide13$11,291
SuboxoneBuprenorphine Hcl/Naloxone Hcl34$10,500
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$10,222
MyrbetriqMirabegron14$6,426
GemtesaVibegron11$5,368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$42$32,51456 claims
PfizerEliquis$307$23,00939 claims
AstraZenecaFarxiga$1,362$21,18873 claims
NovartisEntresto$666$18,44863 claims
Novo NordiskOzempic$443$16,21619 claims
Lilly USA, LLCTrulicity$691$14,00714 claims
AbbVieLinzess$1,228$11,77723 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$334$11,29113 claims
Astellas Pharma US IncMyrbetriq$467$6,42614 claims
Sumitomo Pharma America, Inc.Gemtesa$751$5,36811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →